Initial Evaluation and Management of Acute Coronary Syndromes
Electrocardiographic Assessment
Biomarker and Clinical Assessment
Antiplatelet and Anticoagulant Therapy
| Agent | Dose (generic) | Route | Frequency |
|-------|----------------|-------|-----------|
| Enoxaparin | 1 mg/kg | Subcutaneous | Twice daily |
| Fondaparinux | 2.5 mg | Subcutaneous | Once daily |
| Unfractionated heparin | 60–70 U/kg bolus (max 5,000 U) followed by infusion titrated to aPTT 1.5–2.5 × control | Intravenous | Continuous |
3
Adjunctive Pharmacotherapy
Reperfusion Timing for STEMI
Long‑Term Secondary Prevention (initiated during hospitalization)
Initial Management of Acute Coronary Syndrome (ACS)
Immediate Assessment and Diagnosis
- The European Society of Cardiology recommends obtaining a 12-lead ECG within 10 minutes of presentation to differentiate between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS) 5, 6
- Collect blood samples for high-sensitivity cardiac troponin measurement at presentation (0h) and after 1-3 hours to rapidly rule-in or rule-out myocardial infarction, as recommended by the European Heart Journal 7, 8
- Perform echocardiography to evaluate regional and global left ventricular function and rule out differential diagnoses, according to the European Heart Journal 7, 9
- Monitor cardiac rhythm continuously for detection of arrhythmias, as suggested by the European Heart Journal 10, 5
- Assess vital signs with particular attention to hemodynamic stability and signs of heart failure, as recommended by the European Heart Journal 5, 8
Initial Pharmacological Management
- The European Society of Cardiology recommends administering aspirin 150-300mg loading dose immediately to all patients without contraindications 11, 10
- Initiate a P2Y12 inhibitor in addition to aspirin for 12 months unless contraindicated, as suggested by the European Heart Journal 7, 12
- Administer parenteral anticoagulation with low molecular weight heparin (LMWH) or unfractionated heparin, according to the European Heart Journal 11, 10
- Continue anticoagulation until revascularization is performed or hospital discharge, as recommended by the European Heart Journal 10, 8
- Administer sublingual or intravenous nitrates for ongoing chest pain, as suggested by the European Heart Journal 10, 5
- Initiate beta-blockers in the absence of contraindications (hypotension, bradycardia, acute heart failure), according to the European Heart Journal 11, 10
- Consider calcium channel blockers for patients with contraindications to beta-blockers, as recommended by the European Heart Journal 11, 10
Risk Stratification and Invasive Strategy
- The European Society of Cardiology recommends immediate invasive strategy (<2h) for very high-risk criteria, including hemodynamic instability or cardiogenic shock 7, 8
- Early invasive strategy (<24h) is recommended for high-risk criteria, including rise or fall in cardiac troponin compatible with myocardial infarction 7, 8
- Invasive strategy (<72h) is recommended for intermediate-risk criteria, including diabetes mellitus, renal insufficiency, left ventricular ejection fraction <40%, or congestive heart failure 7, 8
Special Considerations
- For patients with NSTE-ACS and high-risk features, early coronary angiography and revascularization improve outcomes, as suggested by the European Heart Journal 7, 8
- Patients with cardiogenic shock require immediate invasive management regardless of ECG changes or biomarker status, according to the European Heart Journal 5, 8
- Initiate high-intensity statin therapy as early as possible, as recommended by the European Heart Journal 7, 13
Common Pitfalls to Avoid
- Delaying ECG beyond 10 minutes of presentation can lead to missed diagnosis and delayed treatment, as warned by the European Heart Journal 5, 6
- Waiting for troponin results before initiating antiplatelet therapy in high-risk patients can lead to delayed treatment, according to the European Heart Journal 10, 5
- Failing to recognize atypical presentations of ACS, particularly in women, elderly, and diabetic patients, can lead to delayed diagnosis, as suggested by the Circulation journal 6